Overactive Bladder Clinical Trial
Official title:
A Single Blind, Randomised, Controlled Trial to Evaluate the Effectiveness of Transcutaneous Posterior Tibial Nerve Stimulation (TPTNS) in Overactive Bladder (OAB) Symptoms in Women Responders to Posterior Tibial Nerve Stimulation (PTNS)
This study will help to determine the effectiveness of a self-supervised, home-based Transcutaneous Posterior Tibial Nerve Stimulation treatment protocol in maintaining Overactive Bladder (OAB) symptoms improvement in women responders to Posterior Tibial Nerve Stimulation (PTNS)
Conservative management of OAB includes (NICE, 2006): behavioural therapy (bladder training
techniques, prompted voiding, timed voiding…); physical therapy (PFM exercises, Biofeedback,
Neuro Muscular Electrical Stimulation…); lifestyle interventions (weight loss, smoking
cessation…) and fluid advice (fluid balance, reduction of caffeine intake…). Antimuscarinic
agents are recommended if non-pharmacological treatment proves ineffective (NICE, 2006).
However, results of behavioural and physical therapy have been shown to fall off by three
months after treatment (Burgio et al, 1998). Furthermore, less than one third of patients
are compliant with anticholinergic medication after 6 months, mostly due to intolerable side
effects, but also to lack of efficacy (Hampel, 2007; Kelleher et al, 1997).
Patients refractory to conservative regimens are candidates in our Physiotherapy Department
for peripheral Neuromodulation therapy in the form of Percutaneus Tibial Nerve Stimulation
(PTNS). Although its mechanism of action is still poorly understood, its efficacy has been
reported to be comparable to that of the antimuscarinic agents, with an objective success
rate of 60% (Burton, Sajja & Latthe, 2012), but with a better side effect profile.
TPTNS is a non-invasive technique, easily manageable by patients, which lacks some adverse
side effects reported with the use of PTNS, such as bleeding and/or pain at the site of
needle insertion. As the technique is self-administered, the associated costs might be
substantially lower when compared to PTNS, which involves repeated Hospital appointments for
maintenance therapy.
This study will help to determine the effectiveness of a self-supervised, home-based
Transcutaneous Posterior Tibial Nerve Stimulation treatment protocol in maintaining
Overactive Bladder (OAB) symptoms improvement in women responders to Posterior Tibial Nerve
Stimulation (PTNS)
Participants will be assigned to one of the two treatments arms using a computer generated
random number table, with assignments drawn from sealed, opaque, serially numbered
envelopes.
Participants will be recruited from the Physiotherapy Department at the Liverpool Women's
Hospital. Our primary outcome variable will be changes in 24-hour voiding frequency, number
of episodes of urgency, as well as number of episodes of urge urinary incontinence. These
variables can be reliably measured in self-completed 3-day bladder diaries (Gormley et al,
2012).
As OAB is a symptom-based diagnosis, the quality of life (QoL) impact of the symptoms is a
crucial aspect of the condition. We will therefore use as secondary end point the score in
the OAB-q questionnaire, a patient-reported outcome measure (PROM) of symptom severity as
well as Health Related Quality of Life (HRQOL). The OAB-q has shown good content and
construct validity, as well as high internal consistency and good test-retest reliability
(Coyne et al, 2006).
Bladder diaries and the OAB-q questionnaire are routinely used in our Department for all
patients starting on PTNS (T1). Collection of data will be carried out again at the end of
the 12-week course of PTNS. Data obtained at this point (T2) will determine those subjects
who are objective responders and who will be invited to enter the trial and be randomized
into one of the two treatment arms. During the study period, further assessments will be
carried out by the main investigator, who will be blinded to the treatment group allocation,
at 6 weeks (T3), 3 months (T4) and 6 months (T5).
PTNS will be performed bilaterally, inserting a 40 mm x 0.25 mm acupuncture needle (Classic
Plus Sterile Needle, HMD Europe), three finger breaths cephalad to medial malleolus and
posterior to the medial border of the tibia (SP6 acupuncture point). A self-adhesive
electrode will be placed on the medial aspect of the calcaneus. The needle and the electrode
will be attached to a low voltage electrostimulator (AS SUPER 4 digital, Pierenkemper GmbH,
Germany), set up with a pulse duration of 200 μsecs and a frequency of 20 Hz. The amplitude
(0-20 mA, adjustable in steps of 0.1 mA) will be increased until flexion of the first toe or
fanning of all toes is seen, or tingling sensation in the sole of the foot is reported,
always at a tolerable level. Elevation of the Intensity will be allowed whenever the patient
describes fading of the above sensation due to accommodation.
TPTNS will be also applied bilaterally, using two surface self-adhesive electrodes in each
leg, one placed at SP6 and the other placed on the ankle skin behind the medial malleolus.
Electrical stimulation will be applied through a TENS unit (NeuroTrac PelviTone, Verity
Medical Ltd, Hampshire, UK) using the same parameters as in the PTNS group.
An experienced Women's Health physiotherapist will conduct the PTNS sessions in the control
group and will instruct subjects in the TPTNS group in the stimulation technique.
Participants will be provided with a telephone number to contact the research team in case
they have any queries or any difficulty with the use of the TENS unit.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04578899 -
"The Effectiveness of Transvertebral Magnetic Neuromodulation in Patients With Detrusor Overactivity"
|
N/A | |
Active, not recruiting |
NCT03556891 -
Pivotal Study of eCoin for Overactive Bladder With Urgency Urinary Incontinence
|
N/A | |
Not yet recruiting |
NCT05977634 -
Transcutaneous Tibial Nerve Stimulation for Idiopathic Overactive Bladder
|
N/A | |
Completed |
NCT01955408 -
Severity of Overactive Bladder Symptoms in Patients After Synergo Treatment
|
N/A | |
Recruiting |
NCT06201013 -
Efficacy and Safety of Vitamin D in the Treatment of OAB-wet in Children
|
N/A | |
Recruiting |
NCT03727711 -
TPTNS: Home vs Hospital Treatment for Overactive Bladder
|
N/A | |
Completed |
NCT00768521 -
A Study to Test the Effects of Tolterodine Tartrate in Patients With Overactive Bladder (0000-107)
|
Phase 1 | |
Completed |
NCT03625843 -
Mindfulness Exercises to Reduce Anxiety and Pain During Urodynamic Testing
|
N/A | |
Completed |
NCT02211846 -
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder
|
Phase 1 | |
Completed |
NCT02857816 -
PRospective Study to Evaluate EffectivenesS With the NURO™ PErcutaneous Tibial Neuromodulation System in Patients With OAB
|
N/A | |
Completed |
NCT02835846 -
Investigation of the Effect of the Female Urinary Microbiome on Incontinence
|
Phase 4 | |
Withdrawn |
NCT02320201 -
Foot Neuromodulation for Overactive Bladder in Children
|
N/A | |
Completed |
NCT02202031 -
Controlling Urgency Through Relaxation Exercises
|
N/A | |
Not yet recruiting |
NCT01409512 -
Evaluation of Autonomic System Before and After Anticholinergic Treatment in Women With Overactive Bladder
|
N/A | |
Completed |
NCT01437670 -
Observational Study to Estimate the Dry Mouth in OAB Patients With Solifenacin
|
N/A | |
Completed |
NCT01458197 -
A Phase 2 Study to Compare the Efficacy and Tolerability of Tarafenacin 0.2 mg and Tarafenacin 0.4 mg to Placebo in Patients Suffering From Overactive Bladder.
|
Phase 2 | |
Not yet recruiting |
NCT01423838 -
Comparison of Solifenacin and Oxybutynin in the Treatment of Overactive Bladder
|
Phase 4 | |
Withdrawn |
NCT01210859 -
Effects of Antimuscarinic Drugs on Overactive Bladder (OAB) Symptoms After Insertion of Ureteral Stents
|
N/A | |
Terminated |
NCT01758848 -
Physical Therapy for Overactive Bladder
|
N/A | |
Terminated |
NCT01003249 -
Dysfunctional Voiding and Lower Urinary Tract Symptoms With Baclofen
|
Phase 4 |